2023 BiSpecific MAbS Market Report: Market Size, Segments, Share and Growth Factor Analysis, Top Key Players Research Report by Forecast 2032

As per The Business Research Company's BiSpecific MAbS Opportunities And Strategies Market Report 2023, The global bi-specific mAbs market reached a value of nearly $4,462.4 million in 2022, having grown at a compound annual growth rate (CAGR) of 69.9% since 2017. The market is expected to grow from $4,462.4 million in 2022 to $11,811.0 million in 2027 at a rate of 21.5%. The market is then expected to grow at a CAGR of 13.5% from 2027 and reach $22,255.9 million in 2032.

The increasing prevalence of cancer is expected to drive the growth of the bi-specific mAbs market during the forecast period. For example, according to the American Cancer Society, a US-based voluntary health organization, a total of 1.9 million new cancer cases and 609,360 deaths from cancer are expected to occur in the USA in 2022, which is about 1,670 deaths a day. Additionally, according to International Agency for Research on Cancer, a France-based Government agency, by 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Therefore, the increasing prevalence of cancer is expected to propel the growth of the bi-specific MAbs market.

View Complete Report @
https://www.thebusinessresearchcompany.com/report/bispecific-mabs-market

Major companies operating in the bispecific mAbs market are developing innovative products by using advanced technologies to grow in the market. For instance, in August 2022, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, reported that the European Commission (EC) approved conditional marketing authorization (CMA) of Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma (RRMM). Tecvayli is a T-cell redirecting IgG4? bi-specific antibody recognizing BCMA (B-cell maturation antigen) on target cells and CD3e (CD3 Epsilon Subunit Of T-Cell Receptor Complex) on T cells. It is generated based on Ligand's transgenic mouse (OmniAb) and Genmab's DuoBody technology. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics.

The top opportunities in the bi-specific mAbs market segmented by type will arise in the emicizumab segment, which will gain $5,868.3 million of global annual sales by 2027. The top opportunities in segment by indication will arise in the hemophilia A segment, which will gain $5,868.3 million of global annual sales by 2027. The top opportunities in segment by end use will arise in the hospitals segment, which will gain $4,938.8 million of global annual sales by 2027. The bi-specific mAbs market size will gain the most in the USA at $3,483.4 million.

BiSpecific MAbS Market Segmentation:
The BiSpecific MAbS market is segmented by type, by component, by function and by type of traders.

By Type -
a) Catumaxomab (Removab™)
b) Blinatumomab
c) Emicizumab
d) Amivantamab
e) Faricimab
f) Teclistamab

By Indication -
a) Cancer
b) Hemophilia A
c) Ophthalmic

By End-User -
a) Hospitals
b) Research Institutes
c) Other End-Users

Major players in the BiSpecific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson .

The regions covered in the global BiSpecific MAbS market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Download FREE SAMPLE Report - https://www.thebusinessresearchcompany.com/sample_request?id=9886&type=smp

The latest report from The Business Research Company, 'Global BiSpecific MAbS Opportunities And Strategies Market Report - Forecast To 2032,' provides a comprehensive global perspective with data and statistics from 60+ geographies, analyzing 7000+ market segments. The regional and country breakdowns section offers insights into each geography's market analysis, size, historic and forecast growth, and key strategies for industry competitiveness.

BiSpecific MAbS Market Report Table Of Content
1. Executive Summary
2. Table Of Contents
3. List Of Figures
4. List Of Tables
5. Report Structure
……
18. Competitive Landscape and Company Profiles
19. Company Profiles
20. Key Mergers and Acquisitions
21. Opportunities And Strategies
22. Bi-Specific mAbs Market, Conclusions And Recommendations

PURCHASE the report @
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9886

Get to know us better:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.